Conversion between sirolimus and everolimus in heart transplant recipients
Clinical Transplantation2023Vol. 37(11), pp. e15102–e15102
Citations Over Time
Abstract
The conversion ratio of 1:2 observed in our population suggests OHT recipients may require an increased dose of EVL compared with SRL to maintain the same goal trough levels. A conversion between mTORi appeared to improve tolerability and did not lead to clinically significant worsening of any measured lab value.
Related Papers
- → Everolimus-Based Immunosuppression in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Liver Transplantation: A Case Series(2014)39 cited
- → Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus(2020)6 cited
- → 356(2006)5 cited
- → Safety of Early Sirolimus Immunosuppression in Lung Transplantation(2018)1 cited
- → Early or late conversion from CNI-based to everolimus-based immunosuppression and improvements of impaired renal function in heart transplant recipients(2012)